Telogen Effluvium vs Androgenic Alopecia: How to Tell

Telogen effluvium (TE) is a temporary, diffuse shedding condition caused by a physiological stressor that pushes follicles into the resting phase prematurely. Androgenic alopecia (AGA) is a progressive, genetically driven form of patterned thinning caused by DHT-mediated follicular miniaturization. They look different, feel different, and require different responses. And for women on GLP-1 medications, a large real-world study found elevated rates of both simultaneously.

Getting the diagnosis right is not academic. Treating AGA with the TE protocol, or treating TE with AGA protocols, wastes time and money.

The Core Difference

TE is a process disruption. Follicles that are healthy and capable of normal function are interrupted by a stressor (weight loss, surgery, illness, postpartum) and shunted into early rest. Once the stressor resolves and nutritional status recovers, those follicles return to anagen. The follicles themselves are structurally intact.

AGA is follicle damage. Over time, exposure to DHT (dihydrotestosterone) causes follicles to miniaturize: each successive hair cycle produces a shorter, finer, lighter hair. Eventually the follicle can no longer produce a visible hair at all. This process is irreversible without intervention and tends to follow predictable anatomical patterns.

The practical difference: TE recovers when the cause resolves. AGA requires ongoing treatment to stop or slow the progression.

Comparison Table

Feature	Telogen Effluvium (TE)	Androgenic Alopecia (AGA)
Pattern	Diffuse, all-over scalp	Patterned (crown, temples, part line)
Onset	Sudden, usually within weeks of peak shedding	Gradual, over months to years
Trigger	Identifiable stressor 2-4 months prior	Genetic predisposition, androgens
Hair shaft	Normal diameter, white club root	Miniaturized, finer with each cycle
Reversibility	Yes, once stressor resolves	No, progressive without treatment
Typical duration	3-6 months active shedding	Lifelong, worsens over time
Pull test	Positive (multiple telogen hairs)	Negative or weakly positive
Who it affects	Any age, any gender	Genetically predisposed
Response to minoxidil	Limited benefit	Established benefit
Key driver	Physiological stress	DHT follicular sensitivity
Bottom line	Temporary crisis	Permanent progressive condition

Telogen Effluvium: The Recognizable Picture

TE typically presents with:

Acute, diffuse shedding. Not concentrated at the temples or crown. Hair loss from every part of the scalp. The shower drain fills. The brush collects more. The pillow shows hairs in the morning.

An identifiable cause. Usually obvious in retrospect: a significant illness, surgery, rapid weight loss, childbirth, extreme stress, or starting a new medication. The timing follows the 2-4 month delay pattern. The GLP-1 user who started treatment in January and notices shedding in April is experiencing textbook TE onset timing.

A positive pull test. Grip 40-60 hairs between two fingers, pull from scalp to tip. Extracting more than 6 hairs is positive for active TE. The extracted hairs have a distinctive white, club-shaped root (telogen hair) rather than a pigmented anagen root with a sheath.

Normal hair diameter. The hairs that remain are normal width. TE doesn't cause miniaturization. If you look at the hairs you're shedding, they're full-diameter.

A predictable recovery arc. Shedding slows once the trigger resolves. Baby hairs (new anagen growth) appear 3-6 months after peak shedding. Density returns over 6-12 months. Most women see near-complete recovery.

And it feels alarming. The quantity of hair loss in active TE is dramatic. 300-500 hairs a day is not unusual. But the follicles are resting, not dying.

Androgenic Alopecia: What's Different

AGA in women is called female pattern hair loss (FPHL). It looks different from male pattern baldness. Women rarely get the characteristic horseshoe pattern of male AGA. Instead:

Thinning at the crown and part line. The part line widens. The crown thins. The temples may recede slightly. The frontal hairline is usually preserved.

Miniaturizing hairs. New growth in affected areas is finer and shorter than before. Under a dermatoscope, a mix of normal and miniaturized follicles is visible. Over time, affected follicles produce progressively lighter, shorter hairs.

Slow, insidious progression. AGA doesn't have a trigger and recovery. It's a ratchet that tightens with each cycle. Women often first notice it in their 30s or 40s and think it's "just stress" for years before realizing the progression.

Negative or weakly positive pull test. AGA isn't primarily a shedding condition; it's a miniaturization condition. The pull test extracts fewer telogen hairs in AGA.

DHT sensitivity. AGA is driven by follicle sensitivity to dihydrotestosterone. In women, the DHT comes from androgen production (the ovaries, adrenals, and peripheral tissues all contribute). 5-alpha reductase inhibitors (finasteride, dutasteride) and DHT-blocking topicals (saw palmetto) can slow the progression.

Why GLP-1 Users Can Have Both

This is where it gets complicated. And it's clinically important.

A TriNetX real-world cohort study (2025) using data from 67 healthcare organizations and 547,993 matched patients found that GLP-1 users had elevated rates of both conditions:

• Telogen effluvium: adjusted odds ratio 1.76 (95% CI: 1.34-2.32)
• Androgenic alopecia: adjusted odds ratio 1.64 (95% CI: 1.35-1.99)

Having both simultaneously is not uncommon. Here's why:

Women on GLP-1 medications are often in their 40s and 50s, a demographic where underlying, mild AGA is already present (often subclinical). The TE triggered by rapid weight loss creates a period of heavy diffuse shedding. As follicle density drops acutely, the patterned thinning from pre-existing AGA becomes visible for the first time. The dramatic TE shedding "unmasks" the AGA.

Then there's the hormonal mechanism. GLP-1-induced LH/FSH suppression reduces estrogen, which can increase the relative androgenic environment. Lower estrogen means less of the estrogen-mediated suppression of 5-alpha reductase activity. The androgen drive on follicles increases, accelerating AGA in those who are genetically predisposed.

The result: a woman who starts GLP-1 treatment with mild subclinical AGA can end up with active TE layered on top of newly progressed AGA. The two conditions require different interventions.

Diagnostic Clues: Which One Do You Have?

You probably have TE if:

• The shedding started suddenly, 2-4 months after a clear trigger
• Hair is falling from every part of your scalp, not just crown/temples
• Remaining hairs are the same diameter as before
• Pull test is positive across multiple scalp zones
• You've had no significant hair thinning prior to this episode

You probably have AGA if:

• Thinning has been happening slowly for years
• The part line is getting wider, the crown is getting thinner
• New growth in affected areas is finer and lighter than before
• There's a family history of female pattern hair loss
• Pull test is negative but scalp inspection shows density reduction

You may have both if:

• You're 40-60, have had mild, slow thinning for a while, and now have acute heavy shedding following GLP-1 treatment
• The shedding is heaviest at the crown and temples (where AGA is most active)
• Recovery from the acute shedding reveals a less dense scalp than expected

A dermatologist can perform trichoscopy (scalp examination under magnification) to assess follicle diameter variation. In pure TE, all follicles are the same size. In AGA, there's a range from full-diameter to significantly miniaturized. In combined cases, both patterns are visible.

There Is Also a Third Option: Alopecia Areata

Worth mentioning because it changes the treatment approach entirely.

Alopecia areata (AA) is an autoimmune condition where the immune system attacks hair follicles. It presents as patchy, well-defined areas of complete hair loss, not diffuse thinning. There are case reports of AA appearing after semaglutide use. The mechanism is not established, but immune modulation is suspected.

If you have discrete bald patches rather than diffuse thinning, that's a different diagnosis from TE or AGA. AA requires dermatological evaluation and potentially immunosuppressive treatment.

What Each Condition Responds To

For TE:

• Identify and remove the trigger where possible
• Address nutritional deficiencies (ferritin above 70 ng/mL, adequate protein and zinc)
• Topical support for the scalp environment during the shedding phase
• Time: most TE resolves within 6-12 months of trigger removal

For AGA:

• DHT-blocking agents (topical saw palmetto, oral finasteride/dutasteride in women where appropriate)
• Minoxidil (extends anagen phase, established efficacy for AGA)
• Low-level laser therapy as an adjunct
• Accepts that treatment is ongoing: stopping AGA treatments typically reverses gains

For both simultaneously:

• Address nutritional deficiencies (helps both)
• Topical ingredients that address both the follicle environment (TE support) and DHT (AGA support) can serve double duty
• Saw palmetto, for example, inhibits 5-alpha reductase activity (relevant for AGA) while the anti-inflammatory properties support scalp health broadly. The Sudeep 2023 RCT (n=80) found topical saw palmetto reduced hair shedding by 22.19% and increased hair density by 7.61% (p<0.001).
• Minoxidil makes more sense for the AGA component than for TE alone

The PD-5 Complex, formulated for GLP-1-related shedding, includes topical saw palmetto and rosemary extract alongside peptides. Rosemary was shown to perform comparably to minoxidil 2% in a head-to-head RCT (Panahi et al., 2015, n=100). These aren't TE-only ingredients.

When to See a Dermatologist

See a dermatologist rather than self-diagnosing if:

• You're not sure which condition you have (or both)
• Shedding has continued for more than 6 months with no slowing
• Pull test positive in all scalp zones, not just diffuse areas
• You're seeing distinct bald patches (rules in AA)
• Family history of female pattern hair loss is strong and you want baseline trichoscopy documented

A good derm can do trichoscopy in 15 minutes and give you a much clearer picture than pattern recognition alone. The visit is worth it before committing to a treatment protocol for the wrong condition.

Related Reading

• How to treat telogen effluvium: evidence-based interventions for TE specifically
• Complete GLP-1 hair loss guide: the full picture for GLP-1 users
• Is GLP-1 hair loss permanent?: TE vs permanent loss, prognosis explained
• Provant PD-5 Complex: topical serum addressing both the follicle microenvironment and DHT-related mechanisms

---

FAQ

What is the main difference between telogen effluvium and androgenic alopecia?

Telogen effluvium is a temporary disruption: a stressor pushes follicles into the resting phase simultaneously, causing heavy diffuse shedding that resolves after the stressor is removed. Androgenic alopecia is a progressive structural change: DHT causes follicles to miniaturize and produce progressively finer hairs over years. TE resolves on its own; AGA requires ongoing treatment to control.

Can you have telogen effluvium and androgenic alopecia at the same time?

Yes. The TriNetX study of 547,993 matched patients found GLP-1 users had elevated rates of both TE (aOR 1.76) and AGA (aOR 1.64). Women in their 40s and 50s who had subclinical AGA may see it progress rapidly when GLP-1-induced TE reduces overall hair density and the hormonal changes from LH/FSH suppression increase the androgenic environment.

How do I do a pull test?

Grip 40-60 hairs near the root between your thumb and forefinger. Pull firmly and steadily from scalp to tip. Extracting more than 6 hairs is positive for active TE. Look at the root end of the extracted hairs: telogen hairs have a small white club-shaped root with no pigmented sheath. Anagen hairs (pulled from normal cycling) have a pigmented sheath and gel-like root. Most of the hairs extracted in active TE are telogen.

Does telogen effluvium always grow back?

In the majority of cases, yes. TE follicles are resting, not dead or permanently damaged. Once the stressor resolves and nutritional status recovers, follicles return to anagen and density rebuilds over 6-12 months. The exception: very prolonged TE (over 12 months) in some cases, and combined TE/AGA where the AGA component continues even after TE resolves.

Does minoxidil work for telogen effluvium?

Minoxidil was designed for androgenic alopecia, not TE. It extends the anagen phase and is effective for AGA. For pure TE, where the problem is follicles being pushed into rest rather than follicle miniaturization, minoxidil's benefit is less clear and most specialists don't prescribe it as a primary TE treatment. If you have both TE and AGA, minoxidil addresses the AGA component but not the TE cause.

Can GLP-1 medications cause androgenic alopecia?

The TriNetX cohort found an adjusted odds ratio of 1.64 for AGA in GLP-1 users vs matched controls. This doesn't prove causation, but suggests an association. The likely mechanism is the hormonal shift from LH/FSH suppression (lower estrogen increases relative androgenic activity). Women with genetic predisposition to AGA may find that GLP-1-induced hormonal changes accelerate a condition that would otherwise have progressed more slowly.